Intravenous insulin decreases protein breakdown in infants on extracorporeal membrane oxygenation.
OBJECTIVE
Infants requiring extracorporeal membrane oxygenation (ECMO) have the highest rates of protein catabolism ever reported. Recent investigations have found that such extreme protein breakdown is refractory to conventional nutritional management. In this pilot study, the authors sought to use the anabolic hormone insulin to reduce the profound protein degradation in this cohort.


METHODS
Four parenterally fed infants on ECMO were enrolled in a prospective, randomized, crossover trial. Subjects were administered an insulin infusion using a 4-hour hyperinsulinemic euglycemic clamp followed by a control saline infusion on consecutive days in random order. Whole-body protein flux and breakdown were quantified using a primed continuous infusion of the stable isotope L-[1-13C]leucine. Statistical analyses were performed using paired t tests.


RESULTS
Serum insulin levels were increased 15-fold during the insulin clamp compared with the saline control (407 +/- 103 v 26 +/- 12 microU/mL; P <.05). During the insulin infusion, infants had decreased rates of total leucine flux (214 +/- 25 v 298 +/- 38 micromol/kg/h; P <.05) and leucine flux derived from protein breakdown (156 +/- 40 v 227 +/- 54 micromol/kg/h; P <.05) when compared with saline control. Overall, insulin administration produced a 32% reduction in protein breakdown (P <.05).


CONCLUSIONS
In this pilot study, the anabolic hormone insulin markedly reduced protein breakdown in critically ill infants on ECMO. Because elevated protein breakdown correlates with mortality and morbidity, the administration of intravenous insulin may ultimately have broad applicability to the metabolic management of critically ill infants.
Agus
Michael S D
MS
Department of Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Javid
Patrick J
PJ
Ryan
Daniel P
DP
Jaksic
Tom
T
D001786:Blood Glucose / Q000032:analysis; D015331:Cohort Studies; D018592:Cross-Over Studies; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects*; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D006946:Hyperinsulinism / Q000139:chemically induced / Q000378:metabolism; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000628:therapy; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D007930:Leucine / Q000493:pharmacokinetics; D008297:Male; D010289:Parenteral Nutrition, Total; D010865:Pilot Projects; D011446:Prospective Studies; D011506:Proteins / Q000378:metabolism*; D016896:Treatment Outcome
D001786:Blood Glucose; D007328:Insulin; D011506:Proteins; D007930:Leucine; D005947:Glucose